46th week of 2009 patent applcation highlights part 32 |
Patent application number | Title | Published |
20090280032 | IMPROVED MULTI-WELL ASSAY PLATE - The invention relates to the field of analytical chemistry, in particular to multi-well assay plates having a unique flatness for use in high throughput (bio)chemical and biological assays which rely on luminescence detection. Provided is a multi-well assay plate a top layer including walls defining a plurality of adjacent sample wells for receiving assay samples, and a bottom layer defining the bottom of the wells, having a bottom surface facing away from the wells and wherein said bottom surface is provided with a grid structure forming a plurality of mock wells at the plate bottom, characterized in that the total volume of the mock wells is less than the total volume of the sample wells. | 2009-11-12 |
20090280033 | Pipette Tip Mounting And Ejection Assembly And Associated Pipette Tip - An air displacement pipette has a tubular pipette tip with an upper section surrounding a locking chamber, and a body section leading from the upper section and tapering downwardly to a reduced diameter end. A tubular mounting shaft on the pipette has a distal end configured and dimensioned for axial insertion into the locking chamber of the pipette tip. Coacting surfaces on the distal end of the mounting shaft and the upper section of the pipette tip establish an axially interengaged relationship between the pipette tip and the mounting shaft in response to insertion of the distal end of the mounting shaft into the locking chamber. A sleeve is axially shiftable on the mounting shaft between a retracted position accommodating the establishment of the axially interengaged relationship, and an advanced position disrupting the axially interengaged relationship to thereby accommodate axial ejection of the pipette tip from the mounting shaft. | 2009-11-12 |
20090280034 | PROCESS FOR CONTROL OF A SYSTEM FOR METERING AND MIXING A PRODUCT WITH SEVERAL COMPONENTS, AS WELL AS THIS METERING AND MIXING SYSTEM - The system comprises a first alternating pump ( | 2009-11-12 |
20090280035 | BIOLOGICAL ACTIVITY MONITORING AND/OR SUPPRESSION - Ultraviolet radiation is shone within an area and detected. The detected ultraviolet radiation is monitored over a period of time to determine a set of biological activity dynamics for the area. Ultraviolet radiation detected during a calibration period can be used to provide a baseline with which analysis of subsequently detected ultraviolet radiation is compared and analyzed. When the presence of biological activity is determined within the area, ultraviolet radiation and/or one or more other approaches can be utilized to suppress the biological activity. | 2009-11-12 |
20090280036 | Catalytic combustors keeping contained medium warm in response to hydrostatic valve | 2009-11-12 |
20090280037 | Exhaust gas purification apparatus for an internal combustion engine - There is provided a technique which can reduce the NOx stored in an NOx storage reduction catalyst. In case where concentrated reduction is carried out so as to add a reducing agent to the NOx storage reduction catalyst in a concentrated manner when a shift has been made from a state in which reduction of the NOx stored in said NOx storage reduction catalyst is unable to be performed in spite of a request for reduction of the NOx into a state in which reduction of the NOx is able to be performed, the level of concentration upon addition of the reducing agent is changed based on the amount of the NOx stored in the NOx storage reduction catalyst and the temperature of the NOx storage reduction catalyst. | 2009-11-12 |
20090280038 | Fresh scent flowers - Fresh Scent Flowers (Patent Pending) is a faux floral arrangement consisting of plastic, silk, and an air freshener. The pot holding the flowers is made of plastic. The stems for the flowers are plastic and the petals of the flowers are silk. The air freshener is small and compact, fitting neatly underneath the flowers in the flower pot, with air vents at the base of the flowers to allow the aroma to flow freely from the plant/flowers. The air freshener will run on replaceable batteries and replaceable scent cartridges. These can be easily replaced by removing the bottom of the pot which will give access to the air freshener. This as well, will have an on/off switch. | 2009-11-12 |
20090280039 | DEVICE FOR REMOVING POLLUTANTS FROM THE EXHAUST GASES OF A HEAT ENGINE - A device for removing pollutants from exhaust gases of a combustion engine, includes a longitudinal outer casing ( | 2009-11-12 |
20090280040 | PLASMA REACTOR - A plasma chemical reactor is provided. The reactor includes a chamber, a cathode assembly, and a baffle plate. The chamber forms a plasma reaction space. The cathode assembly includes a cathode support shaft and a substrate support. The cathode support shaft is coupled at one side to a wall surface of the chamber. The substrate support is coupled to the other side of the cathode support shaft and supports the substrate. The baffle plate is out inserted and coupled to the substrate support, and has a plurality of vents arranged to be spaced apart and through formed such that reaction gas can pass through, and the vents asymmetrically arranged and formed to get a vent area smaller at an opposite side than a top side of the cathode support shaft. | 2009-11-12 |
20090280041 | Process for the Double Bond Hydroisomerization of Butenes - A process is disclosed for the preferential conversion to 2-butene of a stream containing C4 compounds including 1-butene and 2-butene. The process involves mixing the C4 stream with a first hydrogen stream to form a feed stream, hydroisomerizing the feed stream in the presence of a first hydroisomerization catalyst in order to convert at least a portion of the 1-butene to 2-butene, thereby producing a hydroisomerization effluent, passing the hydroisomerization effluent through a fractionation column to form a top stream comprising isobutane and isobutylene and a bottoms stream comprising 2-butene, withdrawing a recycle stream from said fractionation column at a location above the feed point at which the weight ratio of 1-butene to 2-butene is high, and combining the recycle stream with at least one of the C4 stream and the feed stream upstream from the hydroisomerization catalyst. A corresponding apparatus also is disclosed. | 2009-11-12 |
20090280042 | Controlling Tar By Quenching Cracked Effluent From A Liquid Fed Gas Cracker - In a system for thermal cracking gaseous feedstocks, the system including a gas cracker for producing an effluent comprising olefins, at least one transfer line exchanger for the recovery of process energy from the effluent and a water quench tower system, a process for extending the range of system feedstocks to include liquid feedstocks that yield tar is provided. The process includes the steps of injecting a first quench fluid downstream of a primary transfer line exchanger to quench the process effluent comprising olefins, separating in a first separation vessel a cracked product and a first byproduct stream comprising tar from the quenched effluent, directing the separated cracked product to a water quench tower system and quenching the separated cracked product with a second quench fluid to produce a cracked gas effluent for recovery and a second byproduct stream comprising tar. An apparatus for carrying out such process is also provided. | 2009-11-12 |
20090280043 | Activation device - A device for activating a two component reaction system where the two reaction component are in separate containers with one container inside the other. The containers are sealed from each other and the inner container includes an activation element for opening a part of the seal. A pressure differential between the pressure in the inner and outer containers is made so the inner container has the higher pressure. Opening a part of the seal in the inner container drives the second component to react with the first reaction component. The seal is opened by cutting the inner container. | 2009-11-12 |
20090280044 | Continuous process for purification of brine - A continuous process for purification of brine contaminated with alkaline earth metals. The process comprises combining the brine with an aqueous solution containing at least one of an alkali metal hydroxide and an alkali metal carbonate with efficient mixing by a micro-mixing device. | 2009-11-12 |
20090280045 | Air Purification System Employing Particle Burning - An air purification system includes a reverse flow heat exchanger, a combustion chamber and a means for heating particles configured to cause particles in air to combust in the chamber. The reverse flow heat exchanger transfers excess heat from the purified air to the incoming air to lower the amount of energy needed to combust the particles in the combustion chamber. The means for heating particles can comprise a flame or a microwave emitter. The reverse flow heat exchanger is spiral wound around the combustion chamber. | 2009-11-12 |
20090280046 | APPARATUS AND METHOD TO SEQUESTER CONTAMINANTS - The invention relates to an apparatus and method for reducing contaminants from industrial processes. More particularly, the invention is directed to a method of sequestering pollutants from flue gases in operational plants. The method includes sequestering contaminants from a point source by reacting an alkaline material with a flue gas containing contaminants to be sequestered, wherein the reaction has a rapid mass transfer rate to sequester at least a portion of the contaminants. | 2009-11-12 |
20090280047 | Solid ammonia storage and delivery material - A solid ammonia storage and delivery material A solid ammonia storage material comprising: an ammonia absorbing salt, wherein the ammonia absorbing salt is an ionic salt of the general formula: M | 2009-11-12 |
20090280048 | PRODUCTION OF PYROGENIC METAL OXIDES IN TEMPERATURE-CONTROLLED REACTION CHAMBERS - Pyrogenic metal oxides having consistent quality and consistency between batches are prepared by flame hydrolysis in a reactor whose walls are cooled to below 500° C. | 2009-11-12 |
20090280049 | PURIFYING METHOD FOR METALLIC SILICON AND MANUFACTURING METHOD OF SILICON INGOT - In a purifying method for metal grade silicon, metal grade silicon with a silicon concentration not less than 98 wt % and not more than 99.9 wt % is prepared. The metal grade silicon contains aluminum not less than 1000 ppm and not more than 10000 ppm by weight. The metal grade silicon is heated at a temperature not less than 1500° C. and not more than 1600° C. in an inert atmosphere under pressure not less than 100 Pa and not more than 1000 Pa, and maintained at the temperature in the atmosphere for a predetermined period. | 2009-11-12 |
20090280050 | Apparatus and Methods for Casting Multi-Crystalline Silicon Ingots - Apparatuses and methods for making a multi-crystalline silicon ingot by directional solidification comprising two or more moveable heat shields located beneath the crucible, the heat shields being opened in a controlled manner to remove heat and produce a high quality silicon ingot. | 2009-11-12 |
20090280051 | METHOD AND APPARATUS FOR PRODUCING NITROGEN TRIFLUORIDE - A method for producing nitrogen trifluoride related to the present invention is characterized in that a fluorine gas and an ammonia gas are fed into a tubular reactor and are reacted with each other in the presence of a diluting gas in a gaseous phase under the condition of no catalyst to produce a gas product mainly composed of nitrogen trifluoride and a solid product mainly composed of ammonium fluoride and/or acidic ammonium fluoride, and then the solid product attached to an inner wall of the tubular reactor is removed by means of a device for removing the solid product, which device is mounted to the tubular reactor. | 2009-11-12 |
20090280052 | Binary and Ternary Metal Chalcogenide Materials and Method of Making and Using Same - This invention discloses the synthesis of metal chalcogenides using chemical vapor deposition (CVD) process, atomic layer deposition (ALD) process, or wet solution process. Ligand exchange reactions of organosilyltellurium or organosilylselenium with a series of metal compounds having neucleophilic substituents generate metal chalcogenides. This chemistry is used to deposit germanium-antimony-tellurium (GeSbTe) and germanium-antimony-selenium (GeSbSe) films or other tellurium and selenium based metal compounds for phase change memory and photovoltaic devices. | 2009-11-12 |
20090280053 | Method For Producing Nanoparticles Of Aluminum Spinels, And The Use Thereof - The invention relates to a method for producing nanoparticles of aluminium spinels. According to said method, a salt of a metal, the oxide of which can form a spinel lattice with aluminium oxide, is added to an aqueous solution of aluminium chlorohydrate, the solution is then dried, and calcinated in less than 30 minutes, and the agglomerated material thus obtained is ground. | 2009-11-12 |
20090280054 | COMPOSITION AND PROCESS FOR THE DISPLACEMENT OF HYDROGEN FROM WATER UNDER STANDARD TEMPERATURE AND PRESSURE CONDITIONS - The present invention relates to the production of hydrogen. More particularly, the present invention relates to a composition and process for the displacement of hydrogen from water under standard temperature and pressure conditions. The composition comprises finely divided metal powders (e.g., magnesium, or magnesium and aluminum) and can also contain a chloride salt (e.g., sodium chloride or potassium chloride). The process of the present invention comprises adding a composition of the present invention to water (either water that already contains chloride ions—such as seawater—or, alternatively, with compositions that contain a chloride salt, either fresh water or seawater), at standard temperature and pressure conditions, in order to create hydrogen gas from the displacement of hydrogen from the water. | 2009-11-12 |
20090280055 | Use of Fluorine-Containing Compounds for Diagnostic Purposes Using Imaging Methods - Use of fluorine-containing compounds for the diagnostic detection of inflammatory processes by means of an imaging method, said inflammatory processes being selected from the group consisting of inflammatory processes of the lymphatic system, such as cancers that directly affect the lymph nodes, especially Hodgkin's disease, non-Hodgkin lymphomas, tumor metastases; liver tumors, inflammatory processes in the border zone of infarctions, such as myocardial infarction and stroke, or tumors; inflammation of organs, such as myocarditis, encephalitis, meningitis (cerebral and spinal meninges); multiple sclerosis; inflammations of the gastrointestinal tract, such as Crohn's disease; inflammation of the vessels, such as arteriosclerosis, especially so-called “vulnerable plaques”; detection of abscesses and arthritis. | 2009-11-12 |
20090280056 | Antibodies and immunoconjugates and uses therefor - Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP- | 2009-11-12 |
20090280057 | Combination of Intercalating Organometallic Complexes and Tumor Seeking Biomolecules for DNA Cleavage and Radiotherapy - The invention relates to molecules for treatment and diagnosis of tumors and malignancies, comprising a tumor seeking biomolecule, which is coupled to an intercalating moiety, which is capable of complexing a metal, which metal is preferably a radioactive metal, to the use of these molecules and to therapeutic and diagnostic compositions containing them. | 2009-11-12 |
20090280058 | Delivery Of Double-Stranded RNA Into The Central Nervous System - The present invention provides for compositions and methods for in vivo delivery of a cell-permeable complex to cells of the central nervous system, wherein the cell-permeable complex decreases the level of a functional target protein encoded by a target mRNA molecule. In preferred embodiments of the invention, the cell-permeable complex comprises an siRNA nucleic acid molecule operably linked to a cell-penetrating peptide, wherein the cell-penetrating peptide facilitates transport of the cell-permeable complex across both the blood brain barrier and cell membrane of a target cell. The methods of the invention further encompass the utilization of convection-enhanced delivery methods such as intracerebral clysis (ICC) to deliver the cell-permeable complex to the target cells of the central nervous system. | 2009-11-12 |
20090280059 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | 2009-11-12 |
20090280060 | PHOTOCHROMIC PROBES - The present invention provides photochromic compounds and derivatives thereof as shown in claim | 2009-11-12 |
20090280061 | ESTERS OF 5-AMINOLEVULINIC ACID AS PHOTOSENSITIZING AGENTS IN PHOTOCHEMOTHERAPY - The present invention relates to compounds being esters of | 2009-11-12 |
20090280062 | LONGEVITY-PROMOTING EFFECTS OF ACETIC ACID AND REISHI POLYSACCHARIDE - A composition of acetic acid and a composition of acetic acid and RF | 2009-11-12 |
20090280063 | NOVEL PEI-PEG GRAFT COPOLYMER COATING OF IRON OXIDE NANOPARTICLES FOR INFLAMMATION IMAGING - A nanostructure includes a nanoparticle core ( | 2009-11-12 |
20090280064 | TRANSDERMAL DELIVERY OF OPTICAL, SPECT, MULTIMODAL, DRUG OR BIOLOGICAL CARGO LADEN NANOPARTICLE(S) IN SMALL ANIMALS OR HUMANS - A method and a device are disclosed for transdermal delivery to an animal or human of biological cargo-laden nanoparticles. The particles may include multimodal optical molecular imaging probes. The particles may be delivered by providing them in a form that can be absorbed through the skin and applying them to the skin of an animal or human. The application may be accomplished using biological cargo-laden nanoparticles in a device attachable to the skin. The device may be attached directly to the skin by a device containing a vasodilating agent or agents, or micro needles, or multi-layer time release material. The biological cargo-laden nanoparticles may comprise drugs, vaccines, bio-pharmaceuticals, imaging contrast agents, multimodal imaging contrast agents, biomolecules, or anti-infectives. The device may include a first plurality of different types of biological cargo-laden nanoparticles located in a corresponding second plurality of separate time release layers. | 2009-11-12 |
20090280065 | Uses and Compositions for Treatment of Psoriasis - The invention provides methods, uses and compositions for the treatment of psoriasis. The invention describes methods and uses for treating psoriasis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat psoriasis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment psoriasis in a subject. | 2009-11-12 |
20090280066 | Methods and compounds for the treatment of mucus hypersecretion - A method of treating mucus hypersecretion, the causative factor in chronic obstructive pulmonary disease (COPD), asthma and other clinical conditions involving COPD, comprises administering a compound that inhibits exocytosis in mucus secreting cells or neurones that control or direct mucus secretion. Also described is a compound, for use in the treatment of hypersecretion of mucus, which inhibits mucus secretion by inhibiting mucus secretion by mucus secreting cells, and/or inhibiting neurotransmitter release from neuronal cells controlling or directing mucus secretion. | 2009-11-12 |
20090280067 | CRYSTAL FORM OF 8-HYDROXY-5-[(1R)-1-HYDROXY-2-[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL]AM- INO]ETHYL]-2(1H)-QUINOLINONE MONOHYDROCHLORIDE - Crystal form E of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]-amino]ethyl]-2(1H)-quinolinone monohydrochloride is highly crystalline, easy to prepare, and stable. | 2009-11-12 |
20090280068 | POLYMORPH OF 8-HYDROXY-5-[(1R)-1-HYDROXY-2-[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL]AM- INO]ETHYL]-2(1H)-QUINOLINONE MONOHYDROCHLORIDE - Crystal form D of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]-amino]ethyl]-2(1H)-quinolinone monohydrochloride is highly crystalline, easy to prepare, and stable. | 2009-11-12 |
20090280069 | PROGUANIL TO TREAT SKIN/MUCOSAL DISEASES - Proguanil has been found to have rapid and effective killing activity against a variety of disease-causing micro-organisms. For example, when applied topically, proguanil is particularly effective against | 2009-11-12 |
20090280070 | CHEWING GUM COMPRISING HYDROXYAPATITE - The present invention relates to a chewing gum comprising at least one gum base system, at least one chewing gum additive, and further comprising rod-shaped apatite crystals of the formula Ca | 2009-11-12 |
20090280071 | USE OF REPEAT SEQUENCE PROTEIN POLYMERS IN PERSONAL CARE COMPOSITIONS - A personal care composition is provided and includes an effective amount of a repeat sequence protein polymer. The personal care composition may be a hair care composition, a skin care composition, a nail care composition, a cosmetic composition, or an over-the-counter pharmaceutical composition. | 2009-11-12 |
20090280072 | ORAL STAIN REMOVER AND ORAL COMPOSITION - An oral stain remover which can remove a stain or a dental plaque effectively without a need of brushing the surface of teeth with a toothbrush or the like, and an oral composition containing the stain remover. An oral stain remover contains a salt of ultraphosphoric acid, and an oral composition contains the oral stain remover. | 2009-11-12 |
20090280073 | Method of Enhancing Deposition of Benefit Agents and Providing and/or Enhancing Associated Benefits - The invention relates to a method of enhancing/providing deposition of benefit agents using substantially surfactant free gel compositions comprising these hydrophobic and hydrophilic benefit agents. The method provides or enhances benefits associated with the benefit agents. | 2009-11-12 |
20090280074 | USE OF GLYCYRRHETIC ACID AND/OR GLYCYRRHIZIN FOR PRODUCING COSMETIC PREPARATIONS FOR TANNING THE SKIN - The use of glycyrrhetin and/or glycyrrhizin for producing cosmetic or dermatological formulations for enhancing natural skin browning. | 2009-11-12 |
20090280075 | METHOD FOR INCREASING THE SUN PROTECTION FACTOR OF A COSMETIC AND/OR DERMATOLOGICAL PREPARATION - The present invention relates to a method of increasing the sun protection factor of a cosmetic and/or dermatological preparation, to the use of UV-A filters for increasing the sun protection factor of such a preparation and to specific photoprotective cosmetic and/or dermatological preparations. | 2009-11-12 |
20090280076 | COSMETICS HAVING EXCELLENT USABILITY AND STABILITY AND A METHOD FOR MAKING THE SAME - In the prior cosmetics, the cosmetic product provided with sufficient storage stability together with excellent usability can not be realized, and it has been an actual state that a cosmetic product having sense of non-tackiness etc. and excellent usability has poor storage stability. The present invention provides a cosmetic for providing a cosmetic product having more excellent usability and storage stability as a cosmetic, and a method for making the same. | 2009-11-12 |
20090280077 | COSMETICS HAVING EXCELLENT USABILITY AND STABILITY AND A METHOD FOR MAKING THE SAME - In a prior cosmetic, a cosmetic product provided with sufficient storage stability together with excellent usability can not be realized, and it has been an actual state that a cosmetic product having sense of non-tackiness etc. and excellent usability has poor storage stability. In the present invention, as a cosmetic, a cosmetic for producing a cosmetic product having more excellent usability and storage stability, and a method for making the same, are provided. | 2009-11-12 |
20090280078 | Cosmetic composition to accelerate repair of functional wrinkles - A cosmetic composition consists of a combination of peptides that regenerate the dermal matrix and a rapid acting muscle relaxant derived from the extract of the plant, | 2009-11-12 |
20090280079 | COMPOSITION AND USES THEREOF - Use of a composition comprising oil bodies in the preparation of a formulation for administration to a mammal wherein said composition comprises oil curd 5 extracted from grain plant tissue, said oil curd comprising an aqueous dispersion of oil bodies and associated extrinsic protein material. Preferably, the oil curd is extracted from oat seed material. The composition has useful properties in improving the stability of 10 formulations, in particular in emulsifying such formulations and in improving the aesthetic acceptability of a formulation. Also, the compositions are useful in the delivery of actives into the skin &/or hair and in the regulation of the condition of the skin &/or hair. 15 Processes for the preparation of said composition and formulations are also disclosed. | 2009-11-12 |
20090280080 | Aryl silicone polyester resins as hair glossers - The present invention relates to a series of novel silicone polyesters which are prepared by crosslinking an aryl dimethicone copolyol with a dimer acid. The reaction of the aryl dimethicone copolyol and dimer acid results in a polyester having affinity to oils and provides outstanding gloss on hair. | 2009-11-12 |
20090280081 | JAK/STAT pathway inhibitors and uses thereof - The role of the JAK/STAT signal transduction pathway cellular mechanisms that lead to the onset and progression of degenerative joint diseases or disorders such as osteoarthritis (OA) is disclosed. Certain known effective OA therapeutics such as hymenialdisine, debromohymenialdisine, and its variants and derivatives are shown to function as JAK3-specific inhibitors, which downregulate steady state mRNA levels of key cellular components involved in cartilage degradation. Another JAK3-specific inhibitor, not previously known as an OA therapeutic, is shown to downregulate steady state mRNA levels of various cellular components involved in cartilage degradation in a manner identical to that of the known OA therapeutics. | 2009-11-12 |
20090280082 | METHODS FOR TREATING AUTOIMMUNE DISORDERS - The present invention relates to methods for treating autoimmune disorders. In an embodiment, the invention is directed to a method for treating an autoimmune disorder comprising administering a TCCR agonist. In an embodiment, the autoimmune disorder is at least partially mediated by a Th1 response. In an embodiment, the autoimmune disorder is at least partially mediated by CD8 | 2009-11-12 |
20090280083 | Compounds for the Treatment of Hepatitis C - The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. | 2009-11-12 |
20090280084 | NUCLEOSIDE DERIVATIVES FOR TREATMENT OF CALICIVIRIDAE INFECTIONS, INCLUDING NOROVIRUS INFECTIONS - A method and composition for treating a host infected with a Caliciviridae virus, such as a Norovirus, comprising administering an effective treatment amount of a described modified nucleoside or a pharmaceutically acceptable salt thereof, is provided. | 2009-11-12 |
20090280085 | Long Acting Human Interferon Analogs - Compositions, kits and methods are provided for Interferon analogs in order to promote general health or for therapeutic treatment of diseases. Human interferon analogs are made by fusion of interferon with human serum albumin. The bio-assay shows that the interferon analogs with the same cell protection against viral attack have 3-10 times longer acting function than interferon in vivo. These novel long acting interferon analogs can be used in treatment of patients with viral infection, such as SARS virus, HIV, HCV, HBV, or HAV, and the cancer diseases, such as leukemia and malignant melanoma. They also have a 3-5 times longer shelf-life compared with interferon. | 2009-11-12 |
20090280086 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS - A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided. | 2009-11-12 |
20090280087 | Interferon AlPha And C-Phycocyanin For The Treatment Of Autoimmune Diseases, Allergy And Cancer - The present invention consists of the combination of Interferon alpha and C-Phycocyanin (IFN-α/C-Phyco) for obtaining a pharmaceutical preparation for autoimmune disease, allergy and cancer treatments. The anti-inflammatory, immunomodulator, antioxidant, anti-viral, anti-proliferative and anti-tumoral effects, associated to the regulatory T cell inducer effect demonstrated in this invention is the rationale for the use of the IFN-α/C-Phyco combination in these diseases. | 2009-11-12 |
20090280088 | Method of controlling hair shape - The present invention provides a method for determining or modulating hair morphology and properties of natural wavy and frizzy hair and a method for evaluating or selecting a hair morphology modulator. The present invention provides a method for modulating hair morphology, including controlling an expression of IGFBP-5 gene or IGFBP-5 protein in a human hair follicle. | 2009-11-12 |
20090280089 | Inhibition of the liver tropism of adenoviral vectors - The invention relates to the inhibition of liver tropism of adenoviral vectors, by replacement of the endogeneous HVR5 of hexon protein of said adenoviral vector with an heterologous polypeptide. | 2009-11-12 |
20090280090 | METHODS OF TREATING PIGS WITH BACILLUS STRAINS - Disclosed are methods of administering at least two | 2009-11-12 |
20090280091 | 5-FLUOROURACIL-RESISTANT BACTERIA AND METHOD FOR PRODUCTION THEREOF - The present invention provides a method for producing a cytosine deaminase (CD)-expressing, 5-fluorouracil (5-FU)-resistant microorganism which can grow in anaerobic tumor tissues, can express CD, and has a resistance to 5-FU at a concentration that is at least effective for antitumor activity. More specifically, the method is a method (A) comprising performing subculture or acclimation culture of a CD-expressing microorganism which can grow in anaerobic tumor tissues, in the presence of 5-fluorocytosine (5-FC), or a method (B) comprising (1) performing subculture or acclimation culture of a microorganism which can grow in anaerobic tumor tissues and does not express CD, in the presence of 5-FU to produce a 5-FU-resistant microorganism and (2) transforming the 5-FU-resistant microorganism by introducing a CD gene. The present invention also provides the CD-expressing, 5-FU-resistant microorganism and a pharmaceutical composition comprising the microorganism. | 2009-11-12 |
20090280092 | G-Protein Coupled Receptor 83 As a Molecular Switch for the Induction of Regulatory (immunosuppressive) T-cells - The present invention makes use of the role of the G-protein coupled receptor 83 (GPCR83) in the induction of regulatory T cells (Tregs) during the course of ongoing immune response. The present invention relates to means and methods for identifying compounds that are interacting with the GPCR83 polypeptide, and to compounds capable of functioning as immunomodulators in mammals, in particular humans. In addition, the present invention relates to methods of treatment of a subject, in particular a human, suffering from an undesired immunoreaction. | 2009-11-12 |
20090280093 | COMPOSITIONS AND POPULATIONS OF CELLS OBTAINED FROM THE UMBILICAL CORD AND METHODS OF PRODUCING THE SAME - The present invention relates to populations and compositions of stem and progenitor cells derived from the umbilical cord, and methods of obtaining the same. In some embodiments, one or more entire umbilical cords or sections thereof are subjected to a process where a cell population is derived without prior removal of any blood vessel. The population may be derived using mechanical and chemical means. The presently disclosed process may be applied to a single umbilical cord or to a plurality of umbilical cords, for example, as a batch process. Optionally, this process includes removing some or all cord blood before deriving the population. In some embodiments, presently disclosed cell populations include mesenchymal stem cells derived from Wharton's jelly and endothelial progenitor cells derived from a wall of a blood vessel of an umbilical cord. Optionally, the cell population includes stem cells derived from cord blood. The presently disclosed cell populations and compositions may be banked and/or used in a number of clinical or other applications. Exemplary applications include but are not limited to applications related to regenerative medicine, for screening compounds, for research, and for gene therapy. | 2009-11-12 |
20090280094 | Treatment of Ischemic Diseases Using Erythropoietin - Disclosed is a method for stimulating revascularization in a subject comprising the steps of:
| 2009-11-12 |
20090280095 | CELL CULTURE OF KERATINOCYTES UNDER NON-DIFFERENTIATING CONDITIONS - The present invention relates to a cell culture medium comprising (a) an inhibitor of bone morphogenetic protein-4 (BMP-4) and (b) an inhibitor of pigment epithelium-derived factor (PEDF, also known as SerpinF1). In one embodiment, the inhibitors are antibodies against BMP-4 and PEDF, respectively. The medium allows to culture keratinocytes under non-differentiating conditions. The invention also relates to corresponding methods and kits. As the media and methods disclosed allow for an improved manufacture of keratinocytes, the invention also relates to the treatment of skin wounds and to the manufacture of corresponding medicaments. This will be of advantage for treatment e.g. of burns, ulcers, etc., in which transplantation of keratinocytes or skin is required. | 2009-11-12 |
20090280096 | PANCREATIC ENDOCRINE PROGENITOR CELLS DERIVED FROM PLURIPOTENT STEM CELLS - The invention provides pluripotent cells modified to overexpress Pdx1 and Ngn3. Pluripotent cells include embryonic stem cells and induced pluripotent stem cells. Methods of producing pancreatic endocrine progenitor cells from ES cells or from iPS cells by forced expression of Pdx1 and Ngn3 are provided. Pancreatic endocrine progenitor cells are useful for drug discovery and cell replacement therapy. | 2009-11-12 |
20090280097 | PLURIPOTENT CELLS - Pluripotent cells that are immunopositive for both the neural progenitor marker nestin and a pluripotent cell marker are provided. The cells exhibit rapid doubling times and can be maintained in vitro for extended periods. Also provided are cell cultures containing the pluripotent cells, a method of transplanting human pluripotent cells to a host, and a method of reducing seizure activity in a subject. These pluripotent cells, when transplanted into the ventricle of a host animal, migrate to the site of damage and adopt a suitably corrective phenotype, resulting in both structural and functional restoration. | 2009-11-12 |
20090280098 | COMPOSITION FOR BEVERAGE OR FOOD - It is an object of the present invention to provide a composition for a food or beverage containing a butyric acid bacterium which produces butyric acid and is excellent in intestinal regulation and cellooligosaccharide which serves as a substrate for the butyric acid bacterium and facilitates the production of butyric acid, enhancing an amount of butyric acid produced in intestine and being excellent in functions to improve an enteric environment and protect against an infectious disease. That is, the present invention provides a composition for a food or beverage containing a butyric acid bacterium and cellooligosaccharide and having a function to improve an enteric environment and/or a function to protect against an infectious disease, a composition for a food or beverage wherein the butyric acid bacterium is | 2009-11-12 |
20090280099 | NASOPHARYNGEAL INOCULATE OF PROBIOTICS AND PREBIOTICS FOR TREATMENT OF RESPIRATORY INFECTIONS - The present invention is directed to compositions comprising one or more species of probiotic bacteria, optionally in combination with one or more prebiotics, to methods of preventing and treating respiratory infections in animals by employing such compositions, and to methods of preparing the same. | 2009-11-12 |
20090280100 | Preventive or Therapeutic Agent for Inflammatory Ocular-Surface Diseases - [Problems] The present invention aims to provide a preventive or therapeutic agent for inflammatory ocular-surface diseases. | 2009-11-12 |
20090280101 | Method for conversion of uric acid to allantoin and related enzymes - It is described a polypeptide molecule able to selectively modulate uric acid conversion into S(+)-allantoin. A pharmaceutical composition for treating uric acid related disorders and a process to selectively modulate uric acid conversion into S(+)-allantoin are also disclosed. | 2009-11-12 |
20090280102 | COMPOSITIONS FOR ENHANCING THE ANTIBACTERIAL ACTIVITY OF MYELOPEROXIDASE AND METHODS OF USE THEREOF - Methods and compositions are provided for inhibiting the growth of susceptible microorganisms by contacting the microorganisms, in the presence of a peroxide and chloride or bromide, with myeloperoxidase and at least two activity enhancing agent amino acids. | 2009-11-12 |
20090280103 | REGULATION OF MUSCLE REPAIR - Biochemical signals originating at sites of focal adhesions between muscle fibers are functionally involved in the mechano-dependent governance of muscle gene expression. Herein included information describes a methodology to promote improvements of motor function by combining contraction-related and pharmacological interventions which stimulate focal adhesion signaling and a diagnostic use to identify the responsiveness to treatment of a subject. | 2009-11-12 |
20090280104 | COMPOSITIONS AND METHODS FOR INHIBITING SHIGA TOXIN AND SHIGA-LIKE TOXIN - The present invention provides compositions and methods for treating or preventing infection by shiga toxin producing bacteria. | 2009-11-12 |
20090280105 | Novel Fungal Enzymes - This invention relates to novel enzymes and novel methods for producing the same. More specifically this invention relates to a variety of fungal enzymes. Nucleic acid molecules encoding such enzymes, compositions, recombinant and genetically modified host cells, and methods of use are described. The invention also relates to a method to convert lignocellulosic biomass to fermentable sugars with enzymes that degrade the lignocellulosic material and novel combinations of enzymes, including those that provide a synergistic release of sugars from plant biomass. The invention also relates to methods to use the novel enzymes and compositions of such enzymes in a variety of other processes, including washing of clothing, detergent processes, deinking and biobleaching of paper and pulp, and treatment of waste streams. | 2009-11-12 |
20090280106 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use - This invention provides peptides with novel modifications that provide suitable derivatization sites to improve the pharmacokinetic properties of the peptides. These modified peptides function in vivo as agonists of the VPAC2 receptor. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, for example, type 2 diabetics. | 2009-11-12 |
20090280107 | MODIFIED VITAMIN K-DEPENDENT POLYPEPTIDES - The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described. | 2009-11-12 |
20090280108 | SERUM AMYLOID A PROTEIN IN INFLAMMATION AND OBESITY - The present invention relates to the discovery that acute-phase serum amyloid protein A (A-SAA) is a biomarker for obesity and certain abnormal conditions. The present invention, therefore, provides methods of diagnosing obesity or an abnormal condition in a subject The present invention also provides methods of monitoring the progression of obesity or an abnormal condition in a subject. The present invention also relates to treating obesity or an abnormal condition comprising reducing the levels of active SAA1 and/or SAA2 in a subject in need thereof. | 2009-11-12 |
20090280109 | ILT3 and ILT4-related compositions and methods - This invention provides compositions which comprise at least two of a CD4+CD25+ cell, IL-10, a CD8+CD28− cell and a vitamin D | 2009-11-12 |
20090280110 | Cell Model for Alzheimer's Disease Pathology - The present invention encompasses compositions and methods for studying in cell culture the pathologic changes associated with Alzheimer's disease. The present invention further relates to methods for studying and detecting early events in the conversion of healthy neurons to Alzheimer's disease neurons. | 2009-11-12 |
20090280111 | Isolation of the Mitotic Spindle Matrix and its Methods of Use - The invention encompasses a purified preparation of the mitotic spindle matrix essential for mitotic spindle assembly, which allows for identifying an agent that modulates a cell division and/or differentiation signaling pathway comprising determining the effect of the agent on spindle formation, MT nucleation, or lamin matrix assembly wherein the change in spindle formation, MT nucleation or lamin matrix assembly. | 2009-11-12 |
20090280112 | INHIBITORY EFFECTS OF NORDIHYDROGUAIARETIC ACID (NDGA) ON THE IGF-1 RECEPTOR AND ANDROGEN DEPENDENT GROWTH OF LAPC-4 PROSTATE CANCER CELLS - Disclosed herein are methods and compositions for the treatment of prostate cancer with an IGF-1 receptor kinase inhibitor. Methods are also provided for the treatment of prostate cancer by identifying a level of IGF-1 receptor expression and making a decision whether to treat with an IGF-1 receptor kinase inhibitor. | 2009-11-12 |
20090280113 | TARGET FOR REGULATING MULTIPLE SCLEROSIS - Methods are provided for decreasing demyelinating inflammatory disease in a subject by inhibiting the activity of chemokine-like receptor 1 (CMKLR1). Methods are also provided for screening for agents that find use in treating demyelinating inflammatory disease in a subject. | 2009-11-12 |
20090280114 | PREVENTION OF BRAIN INFLAMMATION AS A RESULT OF INDUCED AUTOIMMUNE RESPONSE - A disease characterized by amyloid aggregation in a patient may be prevented or treated by causing antibodies against a peptide component of the amyloid deposit to come into contact with the aggregated or soluble amyloid. In order to decrease the risk of inflammation in such a method, the Fc receptors of the patient are blocked, preferably by administration of an effective amount of IVIg, prior to the procedure of causing the antibodies to come into contact with the amyloid. | 2009-11-12 |
20090280115 | Dihydropteridinones in the Treatment of Respiratory Diseases - The present invention relates to the use of dihydropteridinones of formula 1 | 2009-11-12 |
20090280116 | HUMANIZED ANTIBODIES AGAINST TL1A - Disclosed are humanized antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function. | 2009-11-12 |
20090280117 | METHODS FOR THE TREATMENT OR PREVENTION OF IMMUNE DISORDERS USING ANTI-CD40 ANTIBODIES - The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand. | 2009-11-12 |
20090280118 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH alphaVbeta5 INTEGRIN - The present invention provides compositions and methods for treating and preventing disease associated with αvβ5 integrin by blocking binding to αvβ5 integrin. | 2009-11-12 |
20090280119 | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis - The invention relates to methods and compositions for treating undifferentiated arthritis (UA) and/or preventing the development of rheumatoid arthritis (RA) in subjects with UA by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule. | 2009-11-12 |
20090280120 | METHODS OF TREATING PROSTATE CANCER WITH ANTI-PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODIES - Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided. | 2009-11-12 |
20090280121 | METHODS OF TREATING DISEASES WHICH ARE MEDIATED BY CUTANEOUS LYMPHOCYTE ANTIGEN POSITIVE CELLS - The present invention relates to methods of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cell. In particular, diseases or disorders including contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous T cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne rosacea, prurigo nodularis, and herpes simplex virus, or combination thereof will benefit from the administration of an IL-31 antagonist. The invention also includes methods of predicting a therapeutically responsive patient population. | 2009-11-12 |
20090280122 | USE OF A VIRUS REGIMEN FOR THE TREATMENT OF DISEASES - The use of a virus regimen, especially an oncolytic regimen for the production of a medicament for the treatment of a disease, especially cancer is described. The virus regimen is applied after reducing, shutting down or modifying functioning of the immune system in a controlled manner. In a preferred embodiment T-cell depletion or T-cell modification is used for controlling the immune system. The T-cell depletor or T-cell modifier is administered either separately or as part of the virotherapy regimen. | 2009-11-12 |
20090280123 | Kinesin polypeptides, polynucleotides encoding same and compositions and methods of using same - An isolated polynucleotide comprising a nucleic acid sequence encoding a KIF18A polypeptide being expressed in mesenchymal stem cells is disclosed. Methods of detecting same are disclosed as well as methods of using same for modulating estrogen signaling in cells. | 2009-11-12 |
20090280124 | Methods for the Diagnosis and Treatment of Preeclampsia - Provided by the present invention are methods for treating and diagnosing preeclampsia, as well as kits for use in diagnosing patients with a higher risk of preeclampsia. | 2009-11-12 |
20090280125 | Prion epitopes and methods of use thereof - Prion peptides comprising prion epitopes and fusions thereof, that display enhanced immunogenicity are described. Also described are methods of treating and diagnosing prion disease. | 2009-11-12 |
20090280126 | PEPTIDE-BASED IMMUNIZATION THERAPY FOR TREATMENT OF ATHEROSCLEROSIS - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies. | 2009-11-12 |
20090280127 | MONOCLONAL ANTIBODIES FOR ENHANCING OR INHIBITING INSULIN-LIKE GROWTH FACTOR-I - The present invention provides αVβ3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same. | 2009-11-12 |
20090280128 | ANTI-ILT7 ANTIBODY - An antibody binding to IPC was obtained by using an animal cell in which a cell membrane protein associatable with ILT7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ILT family molecules and ILT7. The anti-ILT7 antibody of the invention bound to IPC and inhibited the activity thereof. With the anti-ILT7 antibody of the invention, the IPC activity can be inhibited and an interferon-related disease can be treated or prevented. ILT7 expression is maintained even in IPC in the presence of IFNα. Therefore, an inhibitory action of IPC activity by the anti-ILT7 antibody can be expected even in an autoimmune disease patient with an increased production of IFNα. | 2009-11-12 |
20090280129 | HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS - The present application relates to highly concentrated antibody and protein formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The application further describes articles of manufacture containing such formulations and method for using them to treat disorders treatable by the formulated antibody or protein. | 2009-11-12 |
20090280130 | METHOD FOR THE TREATMENT OF ANTHRAX TOXICITY - is a spore-forming Gram positive bacterium that is the causative agent of anthrax infection. Vascular leakage and pleural effusions are hallmarks of the fulminant phase of human anthrax disease following infection. The present invention provides a method of halting, treating, and preventing the rapid toxic effects of human anthrax disease by blocking the VEGF pathway with chemical inhibitors of the VEGFR signaling pathway. The invention is also applicable as an anti-anthrax therapeutic in bio-warfare defense. | 2009-11-12 |
20090280131 | IL-17 Antagonistic Antibodies - An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis. | 2009-11-12 |